Quest Diagnostics Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.38 (market cap $1.96B). The key difference: Quest Diagnostics Inc is far larger — about 13× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| DGX | SOXS | |
|---|---|---|
Market Cap | $25.48B | $1.96B |
Volume | 941,866 | 113,512,541 |
Sector | Health | Leveraged / Inverse |
52-Week High | $247.45 | $988.00 |
52-Week Low | $173.49 | $29.62 |
Typical Hold Time | 56 Days | 11 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $34.39, up 12.22% today, reflecting its inverse leveraged exposure to semiconductor stocks. The technical picture is bearish overall, with moving averages signaling a downtrend. Recent news highlights the fund's volatility and tactical use during semiconductor sector pullbacks, driven by factors like AI demand fluctuations and competitive pressures on chipmakers.
The outlook for SOXS remains highly speculative, suitable only for short-term traders betting against semiconductors. Key risks include the fund's decay from daily rebalancing, reliance on semiconductor volatility, and potential for rapid losses if the sector rallies. Investors should avoid long-term holdings due to structural erosion and elevated volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →